Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
2017 · New England Journal of Medicine · 2,174 citations
https://doi.org/10.1056/nejmoa1709030
M
Michele Del Vecchio
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
330
Papers
12.6K
Citations
50
h-index
119
i10-index
Michele Del Vecchio is an academic researcher from Fondazione IRCCS Istituto Nazionale dei Tumori. The author has contributed to research in topics: Melanoma and MAPK Pathways & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 50, co-authored 281 publications.
ORCID: 0000-0001-9060-2512Papers by this author
worksBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
2017 · The Lancet Oncology · 482 citations
https://doi.org/10.1016/s1470-2045(17)30180-8
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
2023 · Nature Medicine · 180 citations
https://doi.org/10.1038/s41591-023-02583-2
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2023 · Clinical Cancer Research · 162 citations
https://doi.org/10.1158/1078-0432.ccr-22-3145
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024 · Nature Communications · 78 citations
https://doi.org/10.1038/s41467-023-44475-6
Cutaneous melanoma in adolescents and young adults
2018 · Pediatric Blood & Cancer · 39 citations
https://doi.org/10.1002/pbc.27292
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat